Article 1 These Measures are formulated in accordance with the Drug Administration Law of the People's Republic of China, the Implementation Regulations of the Drug Administration Law of the People's Republic of China, and the Special Provisions of the State Council on Strengthening the Supervision and Administration of Food and Other Products in order to strengthen drug safety supervision and ensure the safety of drug use by the public.

The Good Manufacturing Practice for Drugs (revised in 2010) (Order No. 79 of the Ministry of Health) was issued on February 12, 2011. The Good Manufacturing Practice for Drugs (revised in 2010), Order No. 79 of the Ministry of Health of the People's Republic of China, was reviewed and adopted at the ministerial meeting of the Ministry of Health on October 19, 2010. It is now issued and will go into effect as of March 1, 2011. Minister Chen Zhu, January 17, 2011, Chapter I, General Provisions Article 1, in order to standardize the quality management of drug production

Article 1 These Regulations are formulated in accordance with the Pharmaceutical Administration Law of the People's Republic of China and the Regulations for the Implementation of the Pharmaceutical Administration Law of the People's Republic of China in order to strengthen the quality control of pharmaceutical trading, standardize pharmaceutical trading behavior, and ensure the safety and effectiveness of drug use by human beings.

(Adopted at the 7th Meeting of the Standing Committee of the Sixth National People's Congress on September 20, 1984, and revised at the 20th Meeting of the Standing Committee of the Ninth National People's Congress on February 28, 2001. According to the Decision on Amending the Marine Environment Protection Law of the People's Republic of China and Other Seven Laws adopted at the 6th Meeting of the Standing Committee of the Twelfth National People's Congress on December 28, 2013 Amendment to the Decision on Amending the Drug Administration Law of the People's Republic of China adopted at the 14th Meeting of the Standing Committee of the Twelfth National People's Congress on April 24, 2015)

It was learned from the State Food and Drug Administration that from January 1 next year, China will implement the batch issuance system for eight kinds of biological products, including human serum albumin, recombinant hepatitis B vaccine, live attenuated measles vaccine, BCG vaccine, live attenuated oral polio vaccine, adsorbed pertussis, diphtheria and tetanus vaccine. According to relevant sources, this is an important step for China's biological product management standards to be in line with international standards.

With the rapid development of science and technology, the market for bioengineering and new drugs is extremely active. Especially in the past few years, when China has gradually integrated with the world pharmaceutical market, the biomedical industry has risen rapidly. Under the speculation of the stock market, the manufacturing industry, which is dominated by chemical drugs, is rapidly approaching the products of bioengineering technology. Today, with the slow development of chemical innovative drugs, the globalization of bioengineered drugs has become increasingly prominent, and has attracted more attention.